title: Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy.
abstract: Lenalidomide is an immunomodulatory agent which has been approved for multiple myeloma. Lenalidomide is also effective in and tolerated well by patients with follicular lymphoma, diffuse large B-cell lymphoma, and transformed large cell lymphoma. This review summarizes the results of current preclinical and clinical studies of lenalidomide, alone or in combination with the monoclonal antibody rituximab, as a therapeutic option for these three lymphoma types. This review will serve as a tool guiding future clinical investigations to improve survival rates for these three lymphomas.
authors.affiliation: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: Madhav
authors.initials: M
authors.lastname: Desai
authors.forename: Kate J
authors.initials: KJ
authors.lastname: Newberry
authors.forename: Jorge
authors.initials: J
authors.lastname: Romaguera
authors.forename: Liang
authors.initials: L
authors.lastname: Zhang
authors.forename: Zhishuo
authors.initials: Z
authors.lastname: Ou
authors.forename: Michael
authors.initials: M
authors.lastname: Wang
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D056747:Immunomodulation; D000077269:Lenalidomide; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000276:immunology; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D059016:Tumor Microenvironment
chemical_list: D020533:Angiogenesis Inhibitors; D013792:Thalidomide; D000077269:Lenalidomide
references.citation: Blood. 2009 Nov 19;114(21):4713-20
references.pmid: 19786615
references.citation: Cancer Res. 2009 Sep 15;69(18):7347-56
references.pmid: 19738071
references.citation: Recent Pat Anticancer Drug Discov. 2007 Jun;2(2):167-74
references.pmid: 17975653
references.citation: Blood. 2007 Jul 15;110(2):695-708
references.pmid: 17389762
references.citation: N Engl J Med. 1999 Nov 18;341(21):1565-71
references.pmid: 10564685
references.citation: Leukemia. 2011 Dec;25(12):1877-81
references.pmid: 21720383
references.citation: J Clin Oncol. 2008 Oct 20;26(30):4952-7
references.pmid: 18606983
references.citation: Br J Haematol. 2008 Jan;140(1):36-45
references.pmid: 17995965
references.citation: J Clin Oncol. 2006 Sep 20;24(27):4507-14
references.pmid: 16940275
references.citation: Br J Haematol. 2011 Aug;154(4):477-81
references.pmid: 21707581
references.citation: Cancer. 2011 Nov 15;117(22):5058-66
references.pmid: 21495023
references.citation: Cancer Res. 2007 Jan 15;67(2):746-55
references.pmid: 17234786
references.citation: Cancer Immunol Immunother. 2008 Dec;57(12):1849-59
references.pmid: 18392823
references.citation: Nature. 2000 Feb 3;403(6769):503-11
references.pmid: 10676951
references.citation: N Engl J Med. 2002 Jun 20;346(25):1937-47
references.pmid: 12075054
references.citation: Leukemia. 2013 Sep;27(9):1902-9
references.pmid: 23545991
references.citation: Leuk Lymphoma. 2008 Jul;49(7):1238-45
references.pmid: 18452080
references.citation: J Clin Oncol. 2015 Nov 1;33(31):3635-40
references.pmid: 26304886
references.citation: N Engl J Med. 1984 Dec 6;311(23):1471-5
references.pmid: 6548796
references.citation: J Clin Oncol. 2009 Nov 10;27(32):5404-9
references.pmid: 19805688
references.citation: Br J Haematol. 2013 Feb;160(4):487-502
references.pmid: 23252516
references.citation: Microvasc Res. 2005 Jan;69(1-2):56-63
references.pmid: 15797261
references.citation: Am J Hematol. 2009 Sep;84(9):553-9
references.pmid: 19565649
references.citation: Clin Cancer Res. 2005 Aug 15;11(16):5984-92
references.pmid: 16115943
references.citation: Nat Rev Cancer. 2004 Apr;4(4):314-22
references.pmid: 15057291
references.citation: J Clin Oncol. 2008 Nov 10;26(32):5165-9
references.pmid: 18838711
references.citation: J Clin Oncol. 2008 Mar 20;26(9):1544-52
references.pmid: 18285605
references.citation: Blood. 2011 Nov 3;118(18):4771-9
references.pmid: 21860026
references.citation: Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):462-6
references.pmid: 21859554
references.citation: Clin Cancer Res. 2008 Jul 15;14(14):4650-7
references.pmid: 18628480
references.citation: J Clin Oncol. 2006 Jan 20;24(3):431-6
references.pmid: 16365178
references.citation: J Clin Oncol. 2010 Sep 20;28(27):4184-90
references.pmid: 20660832
references.citation: Curr Opin Oncol. 2007 Sep;19(5):433-7
references.pmid: 17762566
references.citation: Hematology Am Soc Hematol Educ Program. 2009;:532-41
references.pmid: 20008238
references.citation: Drugs. 2003;63(8):803-43
references.pmid: 12662126
references.citation: Hematology Am Soc Hematol Educ Program. 2011;2011:498-505
references.pmid: 22160081
references.citation: J Clin Oncol. 2011 Mar 10;29(8):986-93
references.pmid: 21282540
references.citation: Acta Haematol. 2010;123(1):21-9
references.pmid: 19907157
references.citation: Leuk Res. 2006 Jul;30(7):849-58
references.pmid: 16494942
references.citation: Science. 2010 Mar 12;327(5971):1345-50
references.pmid: 20223979
references.citation: Ann Oncol. 2011 Jul;22(7):1622-1627
references.pmid: 21228334
references.citation: Blood. 1992 Aug 1;80(3):758-67
references.pmid: 1638027